US EditionSanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
Sanofi will acquire Dynavax for $2.2 billion to add the adult hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 to its portfolio, targeting a large unvaccinated adult population.
- Sanofi agreed to acquire Dynavax Technologies Corporation for $2.2 billion, paying $15.50 per share in cash on Dec. 24, 2025.
- Sanofi is pursuing the deal to strengthen adult immunization by adding Dynavax's marketed vaccine and pipeline, including Z-1018 which showed comparable efficacy to Shingrix in recent trials; this is Sanofi's second vaccines buy this year after the Vicebio acquisition.
- HEPLISAV-B's two-dose, one-month regimen differentiates it from competitors, with Dynavax reporting $268.4 million in 2024 HEPLISAV-B sales and a 46% market share .
- Markets reacted immediately, with Dynavax shares jumping more than 40% in pre-market trading on Wednesday, while the tender offer has not yet commenced and shareholders are urged to review tender offer materials and related SEC filings.
- Sanofi plans to fund the acquisition with available cash, with completion subject to the Hart-Scott-Rodino waiting period and foreign regulatory filings, and it said this would not affect its 2025 guidance.
28 Articles
28 Articles
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
Dynavax Technologies brings Sanofi a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine, both of which offer differentiation from products marketed by GSK. It’s Sanofi’s second billion-dollar vaccines acquisition of 2025. The post Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition appeared first on MedCity News.
Sanofi To Commence Cash Tender Offer To Acquire Dynavax For $15.50/share
(RTTNews) - Sanofi (SNY, SAN.PA) has entered into an agreement to acquire Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine and differentiated shingles vaccine candidate. Sanofi will commence a cash tender offer to acquire all outs
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
